R-Tech Ueno

May 20, 2013	Start of the patient enrollment of a Phase I/II clinical study of recombinant human serum albumin-containing ophthalmic solution (development code: RU-101) in US for the treatment of severe dry eye
May 14, 2013	R-Tech Ueno Announces Fiscal Year March 2013 Earnings
May 14, 2013	Notice Concerning Stock Split, Adoption of Unit Share System and Partial Amendments to the Articles of Incorporation
May 14, 2013	Summary of Business Results for the Fiscal Year March 2013[Japan GAAP] (Non-consolidated)
May 13, 2013	The results of study on Unoprostone (development code UF-021) for retinitis pigmentosa announced at The Association for Research in Vision and Ophthalmology 2013

R-Tech Ueno's originally developed Rescula® Eye Drops is a glaucoma/ocular hypertension treatment drug that was the first in the world to utilize Prostone.

Head Office: NBF Hibiya Bldg., 10F, 1-1-7 Uchisaiwaicho, Chiyoda-ku, Tokyo 100-0011, Japan